Role of Rad51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non–Small-Cell Lung Cancer Cells
Authors:
- Min-Shao TsaiMTMin-Shao Tsai
- Ya-Hsun KuoYKYa-Hsun Kuo
- Yu-Fan ChiuYCYu-Fan Chiu
- Chao-Min ChengCCChao-Min Cheng
- Szu-Ting LinSLSzu-Ting Lin
- Yun-Wei LinYLYun-Wei Lin
- 1 April 2010
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 77 (4) , 633-643
Abstract
Emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) is a natural anthraquinone derivative found in the roots and rhizomes of numerous plants. It is a tyrosine kinase inhibitor and has anticancer effects on lung cancer. Rad51 plays a central role in homologous recombination, and high levels of Rad51 expression are observed in chemo- or radioresistant carcinomas. Our previous studies have shown that the mitogen-activated protein kinase kinase (MKK) 1/2-extracellular signal-regulated kinase (ERK) 1/2 signal pathway maintains the expression of Rad51. Therefore, in this study, we hypothesized that emodin could enhance the effects of the antitumor antibiotic mitomycin C (MMC)-mediated cytotoxicity by decreasing the expression of Rad51 and the phosphorylation of ERK1/2. Exposure of the human non–small-cell lung cancer H1703 or A549 cell lines to emodin decreased the MMC-elicited phosphorylated ERK1/2 and Rad51 levels. Moreover, emodin significantly decreased the MMC-elicited Rad51 mRNA and protein levels by increasing the instability of Rad51 mRNA and protein. In emodin- and MMC-cotreated cells, ERK1/2 phosphorylation was enhanced by constitutively active MKK1/2 (MKK1/2-CA), thus increasing Rad51 protein levels and protein stability. The synergistic cytotoxic effects induced by emodin combined with MMC were remarkably decreased by MKK1-CA-mediated enhancement of ERK1/2 activation. Depletion of endogenous Rad51 expression by small interfering Rad51 RNA transfection significantly enhanced MMC-induced cell death and cell growth inhibition. In contrast, overexpression of Rad51 protects lung cancer cells from the synergistic cytotoxic effects induced by emodin and MMC. We conclude that suppression of Rad51 expression or a combination of emodin with chemotherapeutic agents may be considered as potential therapeutic modalities for lung cancer.Keywords
This publication has 58 references indexed in Scilit:
- The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent MannerCancer Research, 2008
- Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trialBritish Journal of Cancer, 2007
- Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell GrowthCancer Research, 2005
- Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance statusInvestigational New Drugs, 2005
- Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cellsOncogene, 2003
- Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species productionBiochemical Pharmacology, 2002
- DNA double-strand break repair signalling: The case of RAD51 post-translational regulationCellular Signalling, 2002
- Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutantsCell Death & Differentiation, 2002
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclassesProceedings of the National Academy of Sciences, 2001
- Repair of DNA interstrand cross-linksMutation Research/DNA Repair, 2001